Very-low-dose hepatitis B vaccine in newborn infants: an economic option for control in endemic areas

Lancet. 1987 Jan 3;1(8523):29-31. doi: 10.1016/s0140-6736(87)90712-4.

Abstract

Three 1 microgram or 2 micrograms doses of Merck, Sharp and Dohme plasma vaccine were given to 119 infants of mothers negative for antibody to hepatitis B surface antigen (anti-HBs). Anti-HBs antibodies developed in 25/29 (86%) infants given 1 microgram and in 86/90 (96%) given 2 micrograms doses. Levels of anti-HBs achieved by three 2 micrograms doses were similar to those that have been reported for conventional 10 micrograms doses. Similar levels were recorded from infants of anti-HBs-positive mothers, which suggests that maternal antibody does not interfere with the infant's immune response to low doses of vaccine. Three 2 micrograms doses of vaccine in infancy produce satisfactory immunogenicity and make possible economic control of hepatitis B in endemic areas.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carrier State / prevention & control
  • Clinical Trials as Topic
  • Cross Infection / prevention & control
  • Evaluation Studies as Topic
  • Female
  • Hepatitis Antibodies / analysis
  • Hepatitis B / economics
  • Hepatitis B / prevention & control*
  • Hepatitis B Surface Antigens / immunology
  • Hepatitis B Vaccines
  • Humans
  • Infant, Newborn
  • Injections, Intramuscular
  • Maternal-Fetal Exchange
  • New Zealand
  • Pregnancy
  • Random Allocation
  • Vaccination / economics*
  • Viral Hepatitis Vaccines / administration & dosage*

Substances

  • Hepatitis Antibodies
  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines
  • Viral Hepatitis Vaccines